MX2016002718A - Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). - Google Patents

Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).

Info

Publication number
MX2016002718A
MX2016002718A MX2016002718A MX2016002718A MX2016002718A MX 2016002718 A MX2016002718 A MX 2016002718A MX 2016002718 A MX2016002718 A MX 2016002718A MX 2016002718 A MX2016002718 A MX 2016002718A MX 2016002718 A MX2016002718 A MX 2016002718A
Authority
MX
Mexico
Prior art keywords
keto
imidazopyridine derivatives
rorc modulators
compounds
rorc
Prior art date
Application number
MX2016002718A
Other languages
English (en)
Inventor
Benjamin Fauber
Alberto Gobbi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016002718A publication Critical patent/MX2016002718A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos de la fórmula I o II: (ver Formulas) o sales farmacéuticamente aceptables de los mismos, en donde R1 es un grupo de la fórmula (a), (b), (c), (d), (e) o (f): (ver Formulas) y m, n , X, Y, m, n, X, Y, R1, R2, R3, R4, Rb y Rc son como se definen en la presente. También se describen métodos de preparación de los compuestos y el uso de los compuestos para el tratamiento de enfermedades inflamatorias tales como la artritis.
MX2016002718A 2013-09-11 2014-09-10 Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). MX2016002718A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876305P 2013-09-11 2013-09-11
US201462037516P 2014-08-14 2014-08-14
PCT/EP2014/069234 WO2015036411A1 (en) 2013-09-11 2014-09-10 KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS

Publications (1)

Publication Number Publication Date
MX2016002718A true MX2016002718A (es) 2016-06-08

Family

ID=51494300

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002718A MX2016002718A (es) 2013-09-11 2014-09-10 Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).

Country Status (10)

Country Link
US (1) US9550771B2 (es)
EP (1) EP3044224A1 (es)
JP (1) JP2016534139A (es)
KR (1) KR20160055185A (es)
CN (1) CN105531274A (es)
CA (1) CA2922501A1 (es)
HK (1) HK1223933A1 (es)
MX (1) MX2016002718A (es)
RU (1) RU2016111811A (es)
WO (1) WO2015036411A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419015D0 (en) 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds
CN107614062A (zh) 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
HK1248682A1 (zh) * 2015-05-04 2018-10-19 F. Hoffmann-La Roche Ag 作为rorc调节剂的哒嗪衍生物
CN107531669B (zh) * 2015-05-04 2020-12-18 豪夫迈·罗氏有限公司 作为RORc调节剂的哒嗪衍生物
RS59934B1 (sr) 2015-06-09 2020-03-31 Abbvie Inc Modulatori nuklearnih receptora (ror) za lečenje inflamatornih i autoimunih oboljenja
WO2016198908A1 (en) * 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2120938A4 (en) * 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
ES2659455T3 (es) * 2011-09-19 2018-03-15 ETH Zürich Moduladores del ROR gamma para tratar complicaciones de diabetes II

Also Published As

Publication number Publication date
HK1223933A1 (zh) 2017-08-11
KR20160055185A (ko) 2016-05-17
US9550771B2 (en) 2017-01-24
CA2922501A1 (en) 2015-03-19
EP3044224A1 (en) 2016-07-20
WO2015036411A1 (en) 2015-03-19
US20160272631A1 (en) 2016-09-22
CN105531274A (zh) 2016-04-27
JP2016534139A (ja) 2016-11-04
RU2016111811A (ru) 2017-10-16

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
NZ730724A (en) Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1
MX2020007265A (es) Derivados de rapamicina.
PH12014502788A1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
WO2016011390A8 (en) Irak4 inhibiting agents
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX376894B (es) Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2.
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2017001980A (es) Derivado de quinolina muy puro y metodo para su produccion.
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
MX2016007522A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MX2015011180A (es) Derivados de aril sulfamida y sulfamato como moduladores del receptor huerfano relacionado con el receptor del retinoide (porc).
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
MY169495A (en) Pharmaceutical compositions
AU2018253590A1 (en) Imidazopyridazine compounds
MX2015006926A (es) Derivados de bencil sulfonamida como moduladores del receptor huerfano relacionado con el receptor retinoide (rorc).
MX2016005128A (es) Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes.
EA201690894A1 (ru) Феноксиэтилы
MX2016015247A (es) Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
MX2015017156A (es) Inhibidores de bace.
MX2016008499A (es) Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc).